The HSPA2 Knockout Jurkat Polyclonal Cells provide a CRISPR/Cas9-edited population of Jurkat T lymphocytes with disruption of the HSPA2 gene, creating a loss-of-function model for investigating this ATP-dependent chaperone. As polyclonal knockout cells, they maintain genetic heterogeneity while achieving functional ablation of HSPA2 across the pool, avoiding clonal artifacts. This format is ideal for population-level studies of HSPA2-dependent processes.
The Jurkat host line, derived from a 14-year-old male with acute lymphoblastic leukemia (ALL), is a widely used model for T cell signaling and leukemia. These immortalized cells exhibit immature T lymphoblast characteristics and robust proliferation, making them suitable for CRISPR editing. The HSPA2 knockout in Jurkat cells allows dissection of chaperone function in a leukemogenic environment.
HSPA2 is a molecular chaperone induced by HSF1 under stress, assisting protein folding and preventing aggregation. It interacts with co-chaperones such as HSP40, BAG3, HOP, and HSP90, and stabilizes client proteins including AKT, ERK, and BCL2. Through these interactions, HSPA2 promotes cell survival via the PI3K-AKT and MAPK pathways and inhibits apoptosis by preserving BCL2 and mitigating BAX activity. Its role in protein quality control places it at the nexus of stress adaptation and cell fate decisions.
In Jurkat T cells, HSPA2 likely supports leukemogenicity by sustaining AKT and ERK activity, thereby enhancing proliferation and resistance to apoptosis. Given the elevated proteotoxic stress in malignant cells, HSPA2-mediated chaperoning may be critical for handling misfolded proteins, and its knockout permits direct examination of stress sensitivity and apoptotic thresholds. This model thus reveals HSPA2 dependencies in T cell leukemia biology.
Typical applications include western blot and RT-qPCR validation, flow cytometry for apoptosis and cell cycle, proliferation assays, and drug response profiling. The polyclonal population supports co-immunoprecipitation to map chaperone-client networks and RNA-seq to elucidate transcriptomic shifts. Researchers can employ this model for HSPA2 inhibitor screening, heat shock response studies, and investigation of MAPK/PI3K-AKT signaling in leukemia. For further information, contact Ascent Research.
